Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study

Publication | Closed Access

DOI

1.3K

Citations

References

2015

Year

Charles J. Ryan, Matthew R. Smith, Karim Fizazi, Fred Saad, Peter F.A. Mulders, Cora N. Sternberg, Kurt Miller, Christopher J. Logothetis, Neal D. Shore, Eric J. Small,

The Lancet Oncology

UrologyOncologyPrednisone Versus PlaceboAbiraterone AcetateClinical TrialsPharmacotherapyCancer TreatmentProstatic DiseaseMedicineChemotherapy-naive Men